




# THE ATOMIC REGIMEN IS NOW APPROVED

**TECENTRIQ + chemotherapy\* in stage III dMMR colon cancer<sup>1</sup> brings:**


- The first major advancement to the standard of care in 20 years<sup>2-6</sup>
- The **ONLY** adjuvant immunotherapy regimen in this setting<sup>1,2</sup>

**TECENTRIQ + chemotherapy cut the risk of recurrence or death in half vs chemotherapy alone<sup>1,2†</sup>**



3-year DFS rates are descriptive Kaplan-Meier point estimates and were not tested for statistical difference.

- Primary endpoint: DFS
- Median follow-up: 40.9 months



\*A fluoropyrimidine and oxaliplatin.

†The chemotherapy used in the ATOMIC trial was mFOLFOX6.

‡Stratified by nodal status (N1/N1c vs N2), T stage (Tx, T1-T3 vs T4), and primary tumor location (proximal vs distal).

§Based on stratified log-rank test.

TECENTRIQ + chemotherapy is specifically indicated for stage III dMMR colon cancer.

**NCCN  
RECOMMENDS**

**Category 2A,  
Preferred  
Option**

Atezolizumab (TECENTRIQ) + chemotherapy<sup>||</sup> is an NCCN Category 2A and preferred immunotherapy/chemotherapy<sup>||</sup> option for adjuvant treatment of stage III dMMR/MSI-H colon cancer according to the National Comprehensive Cancer Network® (NCCN®).<sup>7¶\*\*</sup>

<sup>||</sup>FOLFOX or CAPEOX.

<sup>¶</sup>NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way. See the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for detailed recommendations, including other preferred options.

<sup>¶¶</sup>Category 2A: based upon lower-level evidence, there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate. *Category 2A* and *Preferred* are two separate recommendations.

<sup>\*\*</sup>Preferred intervention: interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.

## Indication

TECENTRIQ® (atezolizumab), in combination with a fluoropyrimidine and oxaliplatin, is indicated for the adjuvant treatment of adult and pediatric patients 2 years of age and older with Stage III, mismatch repair deficient (dMMR) colon cancer.

## Select Important Safety Information

Serious and sometimes fatal adverse reactions occurred with TECENTRIQ treatment. Warnings and precautions include severe and fatal immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, dermatologic adverse reactions, nephritis with renal dysfunction, and solid organ transplant rejection. Other warnings and precautions include infusion-related reactions, complications of allogeneic HSCT, and embryo-fetal toxicity.

Please see full [Prescribing Information](#) and additional Important Safety Information throughout.

## ATOMIC: The first and only positive Phase III immunotherapy trial in early-stage colon cancer<sup>1,2</sup>

- ATOMIC was a randomized, multicenter, open-label trial evaluating adjuvant treatment of patients with histologically confirmed, resected stage III dMMR colon cancer
- The trial included 712 patients; 96% were US-based, evaluated at over 300 NCTN\* sites
- Patients were randomized 1:1 to receive either TECENTRIQ + mFOLFOX<sup>†</sup> for 6 months, followed by TECENTRIQ monotherapy for 6 months, or mFOLFOX6 alone for 6 months
- Conducted by the Alliance for Clinical Trials in Oncology, sponsored by the National Cancer Institute (NCI)

\*An NCI organization supporting clinical trials at over 2200 sites in the US and internationally.<sup>3</sup>

<sup>†</sup>mFOLFOX6 standard dosing regimen.

## Safety data were generally consistent with the well-characterized individual profiles<sup>1,2</sup>

- Serious ARs occurred in 52% of patients receiving TECENTRIQ + chemotherapy; the most frequent serious ARs (≥3%) were diarrhea (8%), nausea (6%), abdominal pain (4.9%), peripheral sensory neuropathy (4.6%), and pyrexia (3.8%)
- 17% of patients discontinued TECENTRIQ due to an AR; the most frequent ARs leading to permanent discontinuation were peripheral sensory neuropathy (5%), neuropathy peripheral (3%), and paresthesia (2%)
- The most common ARs (rate ≥20%) in patients who received TECENTRIQ + chemotherapy were nausea (75%), diarrhea (73%), peripheral sensory neuropathy (62%), decreased appetite (48%), abdominal pain (47%), constipation (43%), cough (42%), peripheral neuropathy (38%), dyspnea (35%), stomatitis (34%), vomiting (26%), and pyrexia (21%)

AR=adverse reaction; CAPEOX=capecitabine and oxaliplatin; CI=confidence interval; DFS=disease-free survival; dMMR=deficient mismatch repair; FOLFOX= fluorouracil, leucovorin, and oxaliplatin; HR=hazard ratio; HSCT=hematopoietic stem cell transplantation; mFOLFOX6=modified fluorouracil, leucovorin, and oxaliplatin; MSI-H=microsatellite instability-high; NCTN=National Clinical Trials Network; NE=not estimable.

## Find billing and coding resources for TECENTRIQ on the [Genentech website](#)

## Important Safety Information

### Severe and Fatal Immune-Mediated Adverse Reactions

TECENTRIQ is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death-receptor 1 (PD-1) or the PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. The following immune-mediated adverse reactions may not include all possible severe and fatal immune-mediated reactions.

Immune-mediated adverse reactions can occur in any organ system or tissue and at any time after starting TECENTRIQ. While immune-mediated adverse reactions usually manifest during treatment with TECENTRIQ, they can also manifest after discontinuation of treatment. Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of TECENTRIQ.

Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.

Withhold or permanently discontinue TECENTRIQ depending on severity. In general, if TECENTRIQ requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less, then initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.

### Immune-Mediated Pneumonitis

TECENTRIQ can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation. Immune-mediated pneumonitis occurred in 3% (83/2616) of patients receiving TECENTRIQ alone, including fatal (<0.1%), Grade 4 (0.2%), Grade 3 (0.8%), and Grade 2 (1.1%) adverse reactions. Pneumonitis led to permanent discontinuation of TECENTRIQ in 0.5% and withholding of TECENTRIQ in 1.5% of patients.

Please see full [Prescribing Information](#) and additional Important Safety Information throughout.

 **TECENTRIQ**<sup>®</sup>  
atezolizumab  
840 mg | 1200 mg  
INJECTION FOR IV USE

## Important Safety Information (cont'd)

### ***Immune-Mediated Pneumonitis (cont'd)***

Systemic corticosteroids were required in 55% (46/83) of patients with pneumonitis. Pneumonitis resolved in 69% of the 83 patients. Of the 39 patients in whom TECENTRIQ was withheld for pneumonitis, 25 reinitiated TECENTRIQ after symptom improvement; of these, 4% had recurrence of pneumonitis

### ***Immune-Mediated Colitis***

TECENTRIQ can cause immune-mediated colitis. Colitis can present with diarrhea, abdominal pain, and lower gastrointestinal (GI) bleeding. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies

Immune-mediated colitis occurred in 1% (26/2616) of patients receiving TECENTRIQ alone, including Grade 3 (0.5%) and Grade 2 (0.3%) adverse reactions. Colitis led to permanent discontinuation of TECENTRIQ in 0.2% and withholding of TECENTRIQ in 0.5% of patients. Systemic corticosteroids were required in 50% (13/26) of patients with colitis. Colitis resolved in 73% of the 26 patients. Of the 12 patients in whom TECENTRIQ was withheld for colitis, 8 reinitiated TECENTRIQ after symptom improvement; of these, 25% had recurrence of colitis

### ***Immune-Mediated Hepatitis***

TECENTRIQ can cause immune-mediated hepatitis. Immune-mediated hepatitis occurred in 1.8% (48/2616) of patients receiving TECENTRIQ alone, including fatal (<0.1%), Grade 4 (0.2%), Grade 3 (0.5%), and Grade 2 (0.5%) adverse reactions. Hepatitis led to permanent discontinuation of TECENTRIQ in 0.2% and withholding of TECENTRIQ in 0.2% of patients. Systemic corticosteroids were required in 25% (12/48) of patients with hepatitis. Hepatitis resolved in 50% of the 48 patients. Of the 6 patients in whom TECENTRIQ was withheld for hepatitis, 4 reinitiated TECENTRIQ after symptom improvement; of these, none had recurrence of hepatitis

### ***Immune-Mediated Endocrinopathies***

#### ***Adrenal Insufficiency***

TECENTRIQ can cause primary or secondary adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated

Adrenal insufficiency occurred in 0.4% (11/2616) of patients receiving TECENTRIQ alone, including Grade 3 (<0.1%) and Grade 2 (0.2%) adverse reactions. Adrenal insufficiency led to permanent discontinuation of TECENTRIQ in 1 patient and withholding of TECENTRIQ in 1 patient. Systemic corticosteroids were required in 82% (9/11) of patients with adrenal insufficiency; of these, 3 patients remained on systemic corticosteroids. The single patient in whom TECENTRIQ was withheld for adrenal insufficiency did not reinitiate TECENTRIQ

#### ***Hypophysitis***

TECENTRIQ can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field cuts. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as clinically indicated

Hypophysitis occurred in <0.1% (2/2616) of patients receiving TECENTRIQ alone, including Grade 2 (1 patient, <0.1%) adverse reactions. Hypophysitis led to permanent discontinuation of TECENTRIQ in 1 patient and no patients required withholding of TECENTRIQ. Systemic corticosteroids were required in 50% (1/2) of patients with hypophysitis. Hypophysitis did not resolve in these 2 patients

#### ***Thyroid Disorders***

TECENTRIQ can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement for hypothyroidism or medical management for hyperthyroidism as clinically indicated

Thyroiditis occurred in 0.2% (4/2616) of patients receiving TECENTRIQ alone, including Grade 2 (<0.1%) adverse reactions. Thyroiditis did not lead to permanent discontinuation of TECENTRIQ in any of these patients, but led to withholding of TECENTRIQ in 1 patient. Hormone replacement therapy was required in 75% (3/4) of patients with thyroiditis. Systemic corticosteroids were required in 25% (1/4) of patients with thyroiditis. Thyroiditis resolved in 50% of patients. The single patient in whom TECENTRIQ was withheld for thyroiditis reinitiated TECENTRIQ; this patient did not have recurrence of thyroiditis

Hyperthyroidism occurred in 0.8% (21/2616) of patients receiving TECENTRIQ alone, including Grade 2 (0.4%) adverse reactions. Hyperthyroidism did not lead to permanent discontinuation of TECENTRIQ in any of these patients, but led to withholding of TECENTRIQ in 0.1% of patients. Antithyroid therapy was required in 29% (6/21) of patients with hyperthyroidism. Of these 6 patients, the majority remained on antithyroid treatment. Of the 3 patients in whom TECENTRIQ was withheld for hyperthyroidism, 1 patient reinitiated TECENTRIQ; this patient did not have recurrence of hyperthyroidism

Hypothyroidism occurred in 4.9% (128/2616) of patients receiving TECENTRIQ alone, including Grade 3 (0.2%) and Grade 2 (3.4%) adverse reactions. Hypothyroidism did not lead to permanent discontinuation of TECENTRIQ in any of these patients, but led to withholding of TECENTRIQ in 0.6% of patients. Hormone replacement therapy was required in 81% (104/128) of patients with hypothyroidism. The majority of patients with hypothyroidism remained on thyroid hormone replacement. Of the 17 patients in whom TECENTRIQ was withheld for hypothyroidism, 8 reinitiated TECENTRIQ after symptom improvement

Please see full [Prescribing Information](#) and additional Important Safety Information throughout.

 **TECENTRIQ**<sup>®</sup>  
atezolizumab  
840 mg | 1200 mg  
INJECTION FOR IV USE

## Important Safety Information (cont'd)

### ***Immune-Mediated Endocrinopathies (cont'd)***

Hypothyroidism occurred in 11% (277/2421) of patients with NSCLC and SCLC receiving TECENTRIQ in combination with platinum-based chemotherapy, including Grade 4 (<0.1%), Grade 3 (0.3%), and Grade 2 (5.7%) adverse reactions. Hypothyroidism led to permanent discontinuation of TECENTRIQ in 0.1% and withholding of TECENTRIQ in 1.6% of patients. Hormone replacement therapy was required in 71% (198/277) of patients with hypothyroidism. The majority of patients with hypothyroidism remained on thyroid hormone replacement. Of the 39 patients in whom TECENTRIQ was withheld for hypothyroidism, 9 reinitiated TECENTRIQ after symptom improvement

### ***Type 1 Diabetes Mellitus, Which Can Present With Diabetic Ketoacidosis***

Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated

Type 1 diabetes mellitus occurred in 0.3% (7/2616) of patients receiving TECENTRIQ alone, including Grade 3 (0.2%) and Grade 2 (<0.1%) adverse reactions. Type 1 diabetes mellitus led to permanent discontinuation of TECENTRIQ in 1 patient and withholding of TECENTRIQ in 2 patients. Treatment with insulin was required for all patients with confirmed Type 1 diabetes mellitus and insulin therapy was continued long-term. Of the 2 patients in whom TECENTRIQ was withheld for Type 1 diabetes mellitus, both reinitiated TECENTRIQ treatment

### ***Immune-Mediated Nephritis With Renal Dysfunction***

TECENTRIQ can cause immune-mediated nephritis

Immune-mediated nephritis with renal dysfunction occurred in <0.1% (1/2616) of patients receiving TECENTRIQ alone, and this adverse reaction was a Grade 3 (<0.1%) adverse reaction. Nephritis led to permanent discontinuation of TECENTRIQ in this patient. This patient required systemic corticosteroids. In this patient, nephritis did not resolve

### ***Immune-Mediated Dermatologic Adverse Reactions***

TECENTRIQ can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson syndrome (SJS), DRESS, and toxic epidermal necrolysis (TEN), has occurred with PD-1/PD-L1 blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-exfoliative rashes

Immune-mediated dermatologic adverse reactions occurred in 0.6% (15/2616) of patients receiving TECENTRIQ alone, including Grade 3 (<0.1%) and Grade 2 (0.2%) adverse reactions. Dermatologic adverse reactions led to permanent discontinuation of TECENTRIQ in 0.1% and withholding of TECENTRIQ in 0.2% of patients. Systemic corticosteroids were required in 20% (3/15) of patients with dermatologic adverse reactions. Dermatologic adverse reactions resolved in 87% of the 15 patients. Of the 4 patients in whom TECENTRIQ was withheld for immune-mediated dermatologic adverse reactions, none reinitiated TECENTRIQ

### ***Other Immune-Mediated Adverse Reactions***

The following clinically significant immune-mediated adverse reactions occurred at an incidence of <1% (unless otherwise noted) in patients who received TECENTRIQ or were reported with the use of other PD-1/PD-L1 blocking antibodies

- *Cardiac/Vascular:* Myocarditis, pericarditis, vasculitis
- *Nervous System:* Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy
- *Ocular:* Uveitis, iritis, and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss
- *Gastrointestinal:* Pancreatitis to include increases in serum amylase and lipase levels, gastritis, duodenitis
- *Musculoskeletal and Connective Tissue:* Myositis/polymyositis, rhabdomyolysis and associated sequelae including renal failure, arthritis, polymyalgia rheumatic
- *Endocrine:* Hypoparathyroidism
- *Hematologic/Immune:* Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection, other transplant (including corneal graft) rejection
- *Other:* Myocarditis-Myositis-Myasthenia Gravis (or Myasthenia-Like) Overlap Syndrome, reported as the co-occurrence of either two or all three adverse reactions

### ***Infusion-Related Reactions***

TECENTRIQ can cause severe or life-threatening infusion-related reactions, including anaphylaxis. Monitor for signs and symptoms of infusion-related reactions. Interrupt, slow the rate of, or permanently discontinue TECENTRIQ based on the severity. For Grade 1 or 2 infusion-related reactions, consider using pre-medications with subsequent doses

Infusion-related reactions occurred in 1.3% of patients receiving TECENTRIQ alone, including Grade 3 (0.2%) reactions

The frequency and severity of infusion-related reactions were similar whether TECENTRIQ was given as a single agent, in combination with other antineoplastic drugs, and across the recommended dose range

Please see full [Prescribing Information](#) and additional Important Safety Information throughout.

 **TECENTRIQ**<sup>®</sup>  
atezolizumab  
840 mg | 1200 mg  
INJECTION FOR IV USE

## Important Safety Information (cont'd)

### Complications of Allogeneic HSCT After PD-1/PD-L1 Inhibitors

Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/PD-L1 blocking antibody

Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause)

These complications may occur despite intervening therapy between PD-1/PD-L1 blockage and allogeneic HSCT

Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefits versus risks of treatment with a PD-1/PD-L1 blocking antibody prior to or after an allogeneic HSCT

### Embryo-Fetal Toxicity

Based on its mechanism of action, TECENTRIQ can cause fetal harm when administered to a pregnant woman. There are no available data on the use of TECENTRIQ in pregnant women. Animal studies have demonstrated that inhibition of the PD-L1/PD-1 pathway can lead to increased risk of immune-related rejection of the developing fetus, resulting in fetal death

Verify pregnancy status of females of reproductive potential prior to initiating TECENTRIQ. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment with TECENTRIQ and for at least 5 months after the last dose

### Use in Specific Populations

#### Nursing Mothers

There is no information regarding the presence of TECENTRIQ in human milk, the effects on the breastfed infant, or the effects on milk production. As human IgG is excreted in human milk, the potential for absorption and harm to the infant is unknown

Because of the potential for serious adverse reactions in breastfed infants from TECENTRIQ, advise female patients not to breastfeed while taking TECENTRIQ and for at least 5 months after the last dose

#### Fertility

Based on animal studies, TECENTRIQ may impair fertility in females of reproductive potential while receiving treatment

### Most Common Adverse Reactions

The most common adverse reactions (rate  $\geq 20\%$ ) in patients who received TECENTRIQ in combination with chemotherapy for colon cancer were nausea (75%), diarrhea (73%), peripheral sensory neuropathy (62%), decreased appetite (48%), abdominal pain (47%), constipation (43%), cough (42%), peripheral neuropathy (38%), dyspnea (35%), stomatitis (34%), vomiting (26%), and pyrexia (21%).

You may report side effects to the FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch). You may also report side effects to Genentech at 1-888-835-2555.

Please see full [Prescribing Information](#) for additional Important Safety Information.

**Learn more about the ATOMIC regimen  
for stage III dMMR colon cancer**

[TECENTRIQ.COM/colon](https://TECENTRIQ.COM/colon)



**References:** 1. TECENTRIQ Prescribing Information. Genentech, Inc. 2. Sinicrope FA, Ou F-S, Arnold D, et al. Atezolizumab plus FOLFOX for stage III mismatch repair-deficient colon cancer. *N Engl J Med*. 2026;394:1155-1166. doi:10.1056/NEJMoa2507874 3. Yang L, Yang J, Kleppe A, Danielsen HE, Kerr DJ. Personalizing adjuvant therapy for patients with colorectal cancer. *Nat Rev Clin Oncol*. 2024;21:67-79. 4. Grothey A, Sargent DJ. FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. *J Clin Oncol*. 2005;23:3311-3313. 5. Hirsch BR, Zafar SY. Capecitabine in the management of colorectal cancer. *Cancer Manag Res*. 2011;3:79-89. 6. Sinicrope FA, Ou F-S, Arnold D, et al. Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC). Presented at: Annual Meeting of the American Society of Clinical Oncology; May 30-June 3, 2025; Chicago, Illinois. 7. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V.2.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed April 7, 2026. To view the most recent and complete version of the guideline, go online to [www.NCCN.org](http://www.NCCN.org). 8. NCI's National Clinical Trials Network (NCTN). Cancer.gov. Updated February 27, 2026. Accessed June 16, 2026. <https://www.cancer.gov/research/infrastructure/clinical-trials/nctn>

**Genentech**

A Member of the Roche Group

 **TECENTRIQ**  
atezolizumab 840 mg | 1200 mg  
INJECTION FOR IV USE